Scope Fluidics SA (SCP) - Total Assets
Based on the latest financial reports, Scope Fluidics SA (SCP) holds total assets worth zł141.67 Million PLN (≈ $38.99 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scope Fluidics SA - Total Assets Trend (2015–2024)
This chart illustrates how Scope Fluidics SA's total assets have evolved over time, based on quarterly financial data. Also see SCP market cap overview for the company's overall valuation and market capitalisation.
Scope Fluidics SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Scope Fluidics SA's total assets of zł141.67 Million consist of 90.5% current assets and 9.5% non-current assets. Review Scope Fluidics SA (SCP) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 74.6% |
| Accounts Receivable | zł3.35 Million | 1.9% |
| Inventory | zł1.76 Million | 1.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł9.73 Million | 5.6% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Scope Fluidics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SCP stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scope Fluidics SA's current assets represent 90.5% of total assets in 2024, an increase from 36.2% in 2015.
- Cash Position: Cash and equivalents constituted 74.6% of total assets in 2024, up from 20.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 27.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 5.6% of total assets.
Scope Fluidics SA Competitors by Total Assets
Key competitors of Scope Fluidics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩335.22 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
Scope Fluidics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.21 | 11.26 | 11.22 |
| Quick Ratio | 12.82 | 11.12 | 11.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł108.18 Million | zł61.14 Million | zł25.49 Million |
Scope Fluidics SA - Advanced Valuation Insights
This section examines the relationship between Scope Fluidics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.95 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 70.3% |
| Total Assets | zł172.87 Million |
| Market Capitalization | $94.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scope Fluidics SA's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Scope Fluidics SA's assets grew by 70.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Scope Fluidics SA (2015–2024)
The table below shows the annual total assets of Scope Fluidics SA from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł172.87 Million ≈ $47.58 Million |
+70.33% |
| 2023-12-31 | zł101.49 Million ≈ $27.93 Million |
-70.68% |
| 2022-12-31 | zł346.15 Million ≈ $95.27 Million |
+556.43% |
| 2021-12-31 | zł52.73 Million ≈ $14.51 Million |
+27.67% |
| 2020-12-31 | zł41.31 Million ≈ $11.37 Million |
+50.73% |
| 2019-12-31 | zł27.40 Million ≈ $7.54 Million |
+97.06% |
| 2018-12-31 | zł13.91 Million ≈ $3.83 Million |
-25.60% |
| 2017-12-31 | zł18.69 Million ≈ $5.14 Million |
+188.96% |
| 2016-12-31 | zł6.47 Million ≈ $1.78 Million |
-31.68% |
| 2015-12-31 | zł9.47 Million ≈ $2.61 Million |
-- |
About Scope Fluidics SA
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.